Acadia Pharmaceuticals (ACAD) announced that іt had achieved positive results from a pivotal study known аѕ ADVANCE using its drug pimavanserin tо treat negative symptoms of schizophrenia. The initial market reaction was mixed, based on narrowly achieving statistical significance. However, an opportunity exists tо move forward. On top of that,Read More →